Our study uncovers a previously unrecognized m<sup>5</sup>C-SERPINB5 axis as a central driver of cervical cancer malignancy and chemoresistance, highlighting SERPINB5 as a clinically actionable target to improve outcomes for patients receiving microtubule-targeting chemotherapy. This evidence concerns the gene SERPINB5 and cervical cancer.